The risks of methodology aversion in drug regulation

Area of Science:

• Regulatory Science
• Biostatistics
• Pharmaceutical Policy

Background:

• Drug regulatory agencies rely heavily on statistical expertise for decision-making.
• Emerging challenges include quantitative benefit-risk modeling, innovative trial designs, and data transparency.

Purpose of the Study:

• To highlight the critical need for enhanced statistical expertise in European regulatory agencies.
• To underscore the risks associated with insufficient statistical capabilities.

Main Methods:

• This study is a qualitative analysis based on the current landscape of regulatory science.
• Expert review of evolving methodologies in clinical trials and regulatory assessment.

Main Results:

• Current statistical expertise levels may be insufficient to meet future regulatory demands.
• Failure to enhance expertise poses risks to regulatory decision-making quality and public confidence.

Conclusions:

• Urgent investment in statistical training and resources is essential for European regulatory agencies.
• Proactive enhancement of statistical capabilities will ensure agencies can effectively manage complex challenges and maintain public trust.